Therapeutic Impact of Leptin on Diabetes, Diabetic Complications, and Longevity in Insulin-Deficient Diabetic Mice

Masaki Naito, Junji Fujikura, Ken Ebihara, Fumiko Miyanaga, Hideki Yokoi, Toru Kusakabe, Yuji Yamamoto, Cheol Son, Masashi Mukoyama, Kiminori Hosoda, and Kazuwa Nakao

OBJECTIVE—The aim of the current study was to evaluate the long-term effects of leptin on glucose metabolism, diabetes complications, and life span in an insulin-dependent diabetes model, the Akita mouse.

RESEARCH DESIGN AND METHODS—We cross-mated Akita mice with leptin-expressing transgenic (LepTg) mice to produce Akita mice with physiological hyperleptinemia (LepTg:Akita). Metabolic parameters were monitored for 10 months. Pair-fed studies and glucose and insulin tolerance tests were performed. The pancreata and kidneys were analyzed histologically. The plasma levels and pancreatic contents of insulin and glucagon, the plasma levels of lipids and a marker of oxidative stress, and urinary albumin excretion were measured. Survival rates were calculated.

RESULTS—Akita mice began to exhibit severe hyperglycemia and hyperphagia as early as weaning. LepTg:Akita mice exhibited normoglycemia after an extended fast even at 10 months of age. The 6-h fasting blood glucose levels in LepTg:Akita mice remained about half the level of Akita mice throughout the study. Food intake in LepTg:Akita mice was suppressed to a level comparable to that in WT mice, but pair feeding did not affect blood glucose levels in Akita mice. LepTg:Akita mice maintained insulin hypersensitivity and displayed better glucose tolerance than did Akita mice throughout the follow-up. LepTg:Akita mice had normal levels of plasma glucagon, a marker of oxidative stress, and urinary albumin excretion rates. All of the LepTg:Akita mice survived for >12 months, the median mortality time of Akita mice.

CONCLUSIONS—These results indicate that leptin is therapeutically useful in the long-term treatment of insulin-deficient diabetes. *Diabetes* 60:2265–2273, 2011

Leptin is an adipocyte-derived hormone that is involved in the regulation of food intake and energy expenditure (1). We previously created transgenic mice that overexpress transgenic leptin under the control of the liver-specific promoter (LepTg) (2). The plasma leptin level is stable in LepTg mice and similar to that in obese rodents and humans, suggesting that the phenotypic changes found in these animals are physiologically relevant (3,4). LepTg mice provide a unique experimental system to investigate the chronic in vivo effects of leptin. LepTg mice exhibit increased glucose metabolism, which is accompanied by the activation of insulin signaling in skeletal muscle and the liver (2). These findings indicate that leptin acts as an antidiabetic hormone. We have demonstrated the efficacy of leptin in various mouse models of diabetes (5–8).

Akita mice are an animal model of diabetes caused by pancreatic β-cell failure. Endoplasmic reticulum stress induced by misfolded proinsulin is responsible for the β-cell dysfunction and destruction in Akita mice. Male Akita mice start to develop hyperglycemia as early as weaning, when 71% decrease of β-cell mass is present. Plasma insulin levels in the mice are reduced to 41% of the control mice at 7 weeks of age. The blood glucose levels in male Akita mice increase irreversibly up to 700 mg/dL at 10 weeks of age, and about half the male Akita mice die of extreme hyperglycemia within the 1st year of life (9). Thus, the Akita mouse is a suitable model for evaluating the therapeutic impact of interventions on the onset, progression, and prognosis of diabetes.

In the current study, to clarify how and to what extent chronic leptin therapy affects the long-term course of diabetes, we genetically crossed LepTg and Akita mice to create a unique mouse model of nonobese diabetes with elevated plasma leptin level. Using this mouse diabetes model, we investigated the chronic lifelong effects of leptin on diabetes, diabetic nephropathy, and longevity in Akita mice.

RESEARCH DESIGN AND METHODS

Animals. Generation of LepTg mice was reported previously (2). Briefly, a fusion gene comprising the human serum amyloid P component promoter upstream of the mouse leptin cDNA coding sequences was designed to target hormone expression to the liver (2,8). The highest expressing transgenic line was used in this study (2). The genotype for LepTg mice was determined by PCR (5’-GCTGGTGTGGTTGCTGCTC-3’, 5’-CAAGCTGGAGGACCTGTT-3’). B6-Ins2Akita (Ins2a/jPc5g, referred to hereafter as Akita) mice were purchased from Japan SLC (Shizuoka, Japan). Presence of the Akita mutation was verified by absence of an Fnu4HI restriction site in the PCR product of the Ins2 gene (5’-TGGTGATGCTGGCTGCTGCT-3’, 5’-TGGTCCCATATGCGCAG-3’). Both LepTg and Akita mice were on the same C57BL/6 J background. Hemyzygous male LepTg mice were cross-mated with female heterozygous Akita mice. Male F1 mice were used in this study. Mice were maintained in a temperature-, humidity-, and light-controlled room and allowed free access to standard diet (F-2 diet; Oriental BioService, Kyoto, Japan).

The care of the animals and all experimental procedures were conducted in accordance with the guidelines for animal experiments of Kyoto University and were approved by the Animal Research Committee of Kyoto University. Metabolic parameters measurements. Levels of leptin (Mouse Leptin ELISA, Millipore, St. Charles, MO), glucose (Glutest Neo Super, Sanwa, Nagoya, Japan, or Glucose C2-test, Wako, Osaka, Japan), HbA1c (DCA2000 analyzer, Bayer-Sankyo, Tokyo, Japan), insulin (Ultra-Sensitive PLUS Mouse Insulin Kit, Morinaga, Yokohama, Japan), glucagon (Glucagon EIA Kit, Yamahai, Shizuoka, Japan), triglyceride (TG; Triglyceride E-test, Wako), nonesterified fatty acid (NEFA; NEFA C-test, Wako), β-hydroxybutyrate (Precision Xira, Abbott, Bedford, MA), and thiobarbituric acid reactive substances (TBARS; TBARS...
FIG. 1. Time course of changes in plasma leptin, blood glucose, HbA1c, body weight, and food intake. A: Plasma leptin levels of WT, LepTg, Akita, and LepTg:Akita mice at 8 and 28 weeks of age (n ≥ 4 in each group). B: Sixteen-hour fasting blood glucose levels of WT, LepTg, Akita, and LepTg:Akita mice at 8, 18, and 43 weeks of age (n ≥ 4 in each group). C: Time course of 6-h fasting blood glucose concentrations of WT (◇), LepTg (◆), Akita (○), and LepTg:Akita (●) mice (n ≥ 11 in each group, except n = 5 for data of 40 weeks of age). Since the glucometer has a detection limit up to 600 mg/dL, values above the detection limit were treated as 601 mg/dL. Dashed line indicates detection limit of 600 mg/dL. The numbers along the curves indicate the percent of samples above detection limit. D: Time course of glycated hemoglobin (HbA1c) levels of WT (◇), LepTg (◆), Akita (○), and LepTg:Akita (●) mice (n ≥ 4 in each group). Since the analyzer has a detection limit up to 14%, values above the detection limit were treated as 14.1%. Dashed line indicates detection limit of 14%. The numbers along the curves indicate the percent of samples above detection limit.
Assay Kit, Cayman, Ann Arbor, MI) were measured. Percent body fat was measured by Latheta LTC-100 (ALOKA, Tokyo, Japan). For glucose tolerance tests (GTTs), after 12-h fast, the mice were injected with 1.0 g/kg i.p. glucose. For insulin tolerance tests (ITTs), after a 6-hour fast, the mice were injected with 0.5 units/kg i.p. human insulin (Novo Nordisk, Bagsvaerd, Denmark).

**Pair-feeding experiment.** Akita mice were given the amount of food consumed by ad libitum–fed LepTg:Akita mice on the previous day. A pair-feeding study was conducted from 8 through 11 weeks of age. Body weights and blood glucose concentrations were measured at the end of the period.

**Pancreatic hormone secretion and content.** After 12-h fast, the mice were injected with 3.0 g/kg i.p. glucose. Blood samples were obtained from the retro-orbital venous sinus using heparin-coated glass capillaries. For hormone content, pancreata were homogenized in acid ethanol.

**Histology.** Pancreata were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were immunostained with the following antibodies: guinea pig anti-insulin antibody (Dako, Glostrup, Denmark), rabbit antiguinea pig antibody (Dako), and Alexa488 anti–guinea pig antibody and Alexa546 anti-rabbit antibody (both from Molecular Probes, Eugene, OR). Kidney tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Periodic acid Schiff (PAS) was used to stain 1-μm sections. Mesangial area was determined by the presence of PAS-positive and nuclei-free area in the mesangium. Measurement of the mesangial area of more than 22 glomeruli randomly selected in each mouse was performed with a computer-assisted microscopy (Keyence, Osaka, Japan).

**Albumin in urine.** A metabolic cage was used to collect 24-h urine. Urinary albumin concentration was measured using Alburell M (Exocell, Philadelphia, PA). Blood pressure was measured by the indirect tail-cuff method.

**Survival rates.** Data were analyzed by Kaplan-Meier analysis, and comparisons between genotypes were done by the log-rank test.

**Statistical analyses.** Data are expressed as means ± SE. Comparison between or among groups was by Student's t test, Mann-Whitney U test, or ANOVA with Scheffé F test. P < 0.05 was considered statistically significant.

**RESULTS**

**Generation of LepTg:Akita mice.** Plasma leptin levels were measured periodically (Fig. 1A). At 8 weeks of age, the plasma leptin levels in Akita mice declined to 39% of the levels in WT mice (3.1 ng/mL for WT vs. 1.2 ng/mL for Akita; P < 0.01). Five months later, at 28 weeks of age, an age-dependent increase in plasma leptin levels in WT mice and decrease in Akita mice were observed (18.8 ng/mL for WT vs. 0.58 ng/mL for Akita; P < 0.05). The transgenic expression of leptin was associated with markedly and stably increased plasma leptin levels in both LepTg and LepTg:Akita mice (74.8 ng/mL for LepTg and 64.2 ng/mL for LepTg:Akita at 8 weeks of age and 85.1 ng/mL for LepTg and 65.3 ng/mL for LepTg:Akita at 28 weeks of age).

**Time course of changes in blood glucose and HbA1c levels.** Blood glucose levels were measured after a 16-h fast at 8, 18, and 43 weeks of age (Fig. 1B). Akita mice showed hyperglycemia with blood glucose levels >300 mg/dL even after the 16-h fast at 8 weeks of age, and this hyperglycemia worsened progressively with time. By contrast, the glucose levels remained <160 mg/dL and were indistinguishable between LepTg:Akita and WT mice at all times studied.

Six-hour fasting blood glucose levels, which correlate closely with the daily averaged blood glucose level, and HbA1c levels were followed for ~10 months (Fig. 1C and D). In Akita mice, 6-h fasting blood glucose levels were >500 mg/dL after 10 weeks of age, and more than half of the mice had blood glucose levels >600 mg/dL after 15 weeks of age (Fig. 1C). The blood glucose levels were lower in LepTg:Akita mice than in WT mice at 5 weeks of age and increased gradually after 10 weeks of age but remained <400 mg/dL at 40 weeks of age (Fig. 1C). The 6-h fasting blood glucose levels were 552.4 ± 24.1 mg/dL in LepTg:Akita, 321.0 ± 39.6 mg/dL in LepTg:Akita, 130.3 ± 11.8 mg/dL in LepTg:Akita, and 128.3 ± 3.0 mg/dL in WT mice from 5 to 40 weeks of age. Thus, the average blood glucose level in LepTg:Akita mice was ~58.1% of that in Akita mice.

HbA1c levels changed in a similar pattern to the 6-h fasting blood glucose levels (Fig. 1D). By 8 weeks of age, Akita mice had markedly elevated HbA1c levels (8.4 ± 1.0%), whereas HbA1c levels were the same in LepTg:Akita mice (3.7 ± 0.1% as in WT mice (3.8 ± 0.4%) at that age. Of Akita mice >16 weeks of age, >22% had HbA1c levels above the detection limit (14%). The HbA1c levels of LepTg:Akita mice were ~39.6 mg/dL in LepTg:Akita, 136.3 ± 43.6 mg/dL in LepTg:Akita, 120.7 ± 43.6 mg/dL in LepTg:Akita, and 110.7 ± 43.6 mg/dL in WT mice at the end of 3 weeks of pair feeding (n = 4 in each group). Data are expressed as means ± SE. In A–F, *, † < 0.05, †† < 0.01 for WT vs. LepTg, ‡ < 0.05, §§ < 0.01 for WT vs. Akita, †** < 0.05 for WT vs. LepTg:Akita, †*** < 0.01 for LepTg vs. LepTg:Akita, ††** < 0.05 for Akita vs. LepTg:Akita, and ††*** < 0.01 for Akita vs. LepTg:Akita. In G and H, ††# < 0.01 for Akita vs. pair-fed Akita and *** < 0.01 for LepTg:Akita vs. pair-fed Akita.
FIG. 3. Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. 

A: Plasma insulin (open bars) and glucose (black lines) concentrations after glucose (3 g/kg i.p.) injection in WT, LepTg, Akita, and LepTg:Akita mice at 8 weeks of age (n ≥ 4 in each group).

B: Plasma glucagon concentration in ad libitum–fed WT, LepTg, Akita, and LepTg:Akita mice at 22 weeks of age (n ≥ 4 in each group).

C and D: Pancreatic insulin (C) and glucagon (D) content measured in acid-ethanol extracts of homogenized pancreas from WT, LepTg, Akita, and LepTg:Akita mice at 18 weeks of age (n ≥ 5 in each group).

E: Double immunofluorescent stainings against insulin (green) and glucagon (red) in pancreatic sections from WT, LepTg, Akita, and LepTg:Akita mice at the age of 18 weeks. Scale bar indicates 50 μm.

F: α-Cell and β-cell areas per islet.
Akita mice were elevated compared with WT mice; however, they remained >4% lower than those of Akita mice, even at 40 weeks of age (Fig. 1D). Average HbA1c levels were 11.4 ± 0.9% in Akita, 7.5 ± 1.1% in LepTg:Akita, 3.9 ± 0.3% in LepTg, and 4.1 ± 0.9% in WT mice from 5 to 40 weeks of age.

**Time course of body weight and food intake.** The body weight of all groups of mice increased gradually from birth (Fig. 1E). LepTg:Akita mice weighed significantly less than did Akita mice from 5 to 20 weeks of age. Akita mice lost body weight after 20 weeks of age. Percent body fat at 18 weeks of age was 27.6 ± 1.9, 29.9 ± 0.5, 2.1 ± 0.5, and 1.0 ± 0.4% for WT, LepTg, Akita, and LepTg:Akita mice, respectively.

The food intake of Akita mice was nearly double that of the other three groups of mice during the observation period (Fig. 1F). Food intake did not differ significantly between the WT, LepTg, and LepTg:Akita mice at any time during the study.

**Pair-feeding experiments.** To investigate whether leptin’s ability to decrease food intake is the main reason for its efficacy in improving diabetes, Akita mice were pair fed to achieve the ad libitum food intake of LepTg:Akita mice for from 3 weeks to 8 weeks of age. Although pair feeding reduced the body weight of Akita mice to that of LepTg:Akita mice (Fig. 1G), it did not significantly improve the blood glucose levels in the Akita mice (Fig. 1H).

**Glucose tolerance and insulin sensitivity.** GTTs were performed to evaluate glucose metabolism further (Fig. 2A). At 8 weeks of age, Akita mice had reduced glucose tolerance; however, LepTg:Akita mice exhibited normal glucose tolerance similar to that of the LepTg and WT mice of the same age. At 16 weeks of age, Akita mice developed more severe glucose intolerance than that at 8 weeks of age. Although glucose tolerance was impaired in 16-week-old LepTg:Akita mice compared with that of LepTg and WT mice, it was better than that of 8- and 16-week-old Akita mice. These results indicate that hyperleptinemia significantly improved glucose tolerance during the progressive course of diabetes in Akita mice.

ITTs were performed to determine whether the improved glucose tolerance observed in LepTg:Akita mice was associated with insulin sensitivity (Fig. 2B). At 8 weeks of age, both LepTg and LepTg:Akita mice showed similar, exaggerated hypoglycemic responses to insulin relative to WT and Akita mice (Fig. 2C). At 18 weeks of age, the effect of insulin was blunted in LepTg mice compared with that in LepTg:Akita mice and was comparable with those in WT and Akita mice. At 28 weeks of age, glucose responses to insulin in LepTg and WT mice were severely impaired compared with those in Akita and LepTg:Akita mice. Insulin sensitivities in LepTg and WT mice deteriorated in parallel with advancing age and increasing body weight. In contrast, insulin sensitivities in Akita mice did not deteriorate with age, and the enhanced sensitivity in LepTg:Akita mice did not change at all during the course of our study.

**Secretion and production of insulin and glucagon.** Insulin secretion in response to a maximal glucose challenge was assessed. Plasma insulin levels were measured after an injection of glucose (3 g/kg body wt i.p.) (Fig. 3A). The fasting insulin levels were similar in LepTg, Akita, and LepTg:Akita mice at 8 weeks of age, and all were significantly lower than in WT mice at the same age.

However, the fasting plasma insulin-to-glucose ratio was about three times higher in LepTg:Akita mice than in Akita mice. Both WT and LepTg mice showed an acute insulin response to glucose, Akita mice had virtually no response, and LepTg:Akita mice maintained a slow and slight response.

Plasma glucagon concentration was measured in ad libitum–fed mice at 22 weeks of age (Fig. 3B). Despite marked hyperglycemia, the glucagon level in Akita mice was nearly twice that in WT and LepTg mice. By contrast, LepTg:Akita mice had a normal plasma glucagon level, equivalent to that in the WT and LepTg mice.

Total pancreatic insulin contents of the Akita and LepTg:Akita mice decreased similarly to about one-tenth of those in the WT and LepTg mice (Fig. 3C). The pancreatic glucagon content of the Akita mice was twice that of the WT and LepTg mice; the glucagon content of the LepTg:Akita was half that in Akita mice (Fig. 3D).

**Immunohistochemical examination of the pancreas revealed that Akita mice had profoundly abnormal islet histology with few active β-cells and a higher proportion of α-cells compared with WT and LepTg mice (Fig. 3E and F).** LepTg:Akita mice had fewer β-cells, but α-cell hyperplasia was suppressed relative to Akita mice (Fig. 3E and F). These characteristics agree with the plasma hormone levels (Fig. 3A and B) and pancreatic hormone contents (Fig. 3C and D).

**Lipids and ketones.** Transgenic leptinemia did not significantly affect plasma levels of TG, NEFA, and β-hydroxybutyrate in WT mice (Fig. 4A–C). Akita mice had lower levels of both NEFA and β-hydroxybutyrate, possibly reflecting their lower adipose mass (Fig. 4B and C). None of the Akita mice developed ketonuria as determined by a urine ketone dipstick test (data not shown). In the Akita mice, leptin significantly decreased plasma TG levels by half (LepTg:Akita 37.4 ± 11.6 vs. Akita 89.4 ± 13.6 mg/dL; P < 0.05) (Fig. 4A) but did not change plasma NEFA or β-hydroxybutyrate levels (Fig. 4B and C).

**Systemic oxidative stress.** The plasma level of TBARS was examined as a marker of systemic oxidative stress (Fig. 4D). Akita mice exhibited the highest TBARS levels (35.1 ± 4.9 μmol/L) of the four genotypes at 18 weeks of age; the plasma TBARS levels were similar in WT, LepTg, and LepTg:Akita mice (WT 12.7 ± 1.3, LepTg 16.3 ± 1.8, and LepTg:Akita 17.8 ± 2.3 μmol/L).

**Diabetic nephropathy.** The renoprotective effects of leptin were investigated in Akita mice (Fig. 5A). Akita mice developed overt albuminuria at 12 weeks of age, and urinary albumin excretion was >200 μg/day during the follow-up period. By contrast, the increase in albuminuria was largely attenuated in LepTg:Akita mice throughout the follow-up period. The increase in mesangial matrix (defined as mesangial area) observed in Akita mice was prevented completely in LepTg:Akita mice at 22 weeks of age (Fig. 5B and Table 1). Systolic and diastolic blood pressure and heart rates did not differ significantly between the four groups of mice (Table 1).

---

*Data are expressed as means ± SE. †P < 0.01 for WT vs. LepTg, §§P < 0.01 for WT vs. Akita, ††P < 0.05, ‡‡P < 0.01 for WT vs. LepTg:Akita, ¥P < 0.05, ¥¥P < 0.01 for LepTg vs. Akita, *P < 0.05, **P < 0.01 for LepTg vs. LepTg:Akita, and ***P < 0.01 for Akita vs. LepTg:Akita. (A high-quality digital representation of this figure is available in the online issue.)*
treatment of diabetes of different etiology and pathophysiology (2,5–8,11–13). Leptin effectively improves glucose and lipid metabolism in streptozotocin (STZ)-induced insulinopenic diabetic mice (7) and in mildly obese mice fed a high-fat diet and administered low-dose STZ (6). Transgenic overexpression of leptin can delay the onset of insulin resistance and diabetes in KKAy mice at younger ages, when they are of normal weight (8). These findings suggest that leptin alone is effective in treating diabetes without obesity-induced leptin resistance. We also found that transgenic overexpression of leptin can rescue insulin resistance and diabetes in a mouse model of lipoatrophic diabetes, showing that leptin should be effective in the treatment of lipoatrophic diabetes (5). Therapeutic lep- tinemia can be achieved clinically by subcutaneous injection of recombinant human leptin (11,12). Leptin has been used in the treatment of human diabetes in patients with leptin deficiency and lipodystrophy (11–14).

Leptin delayed the onset and progression of diabetes in Akita mice. Hyperglycemia after a 16-h fast was prevented completely for >10 months in LepTg:Akita mice. The onset of the increase in the 6-h fasting blood glucose and HbA1c levels was also delayed for at least several weeks. Good metabolic control was achieved after the onset of diabetes in LepTg:Akita mice. There are several possible explanations for this glucose-lowering effect of leptin. This study demonstrated that the constitutive hyperleptinemia (approximately 10 times higher than control) strongly and stably increased insulin sensitivity in Akita mice. Leptin increases the effects of insulin in suppressing hepatic glucose production and stimulating muscular glucose uptake (2). The mechanisms through which leptin regulates insulin signaling are not understood completely, although reduction in ectopic fat deposition, especially in the liver and muscle, and activation of AMP-activated protein kinase in the peripheral tissues via stimulation of the hypothalamic-autonomic nervous system are important components (6,15,16). Increased mitochondrial biogenesis and oxygen consumption in skeletal muscle and adipose tissue may also contribute to the increase in glucose disposal independent of insulin action (15,17,18).

Previous studies also demonstrated the antidiabetic effects of leptin in insulin-deficient diabetic rodents (19,20). This study showed no attenuation of the biological effects of leptin (increase in insulin sensitivity and decrease in food intake) in Akita mice throughout the long follow-up. Most of the obese patients have elevated plasma leptin levels (21,22), implying leptin resistance for weight control (23). The basis for such leptin resistance is not understood enough, although such resistance coexists with hyperinsulinemia and insulin resistance (24). This context suggests that leptin has potent therapeutic effects on insulin-deficient diabetes with minimum insulin intervention (7). We and others reported that exogenously administered leptin can normalize hyperglycemia in STZ-induced diabetes, when fed plasma insulin levels were >0.10 ng/mL (7,25). The glycemic control of LepTg:Akita mice worsened gradually when the plasma insulin levels became extremely low (<0.10 ng/mL). These results show that the threshold of plasma insulin level is ~0.10 ng/mL above which leptin can prevent hyperglycemia.

Akita mice, which have low plasma insulin and leptin levels, have increased food intake. Transgenic hyperleptinemia prevented hyperphagia in Akita mice. Although short-term food restriction did not affect hyperglycemia in Akita mice, continuous reduction in food intake might

**DISCUSSION**

The current study demonstrates that transgenic expression of leptin raised its plasma concentration to the level observed in morbibly obese individuals, markedly reduced mortality, and prolonged the survival time in Akita mice. The extension of life span in LepTg:Akita mice was accompanied by various beneficial effects on the course of diabetes.

We have pursued the therapeutic potential of leptin as an antidiabetic agent using transgenic skinny mice and propose that leptin could be used therapeutically in the development of a pancreatic disease model of type 1 diabetes. The extension of life span in LepTg:Akita mice was accompanied by various beneficial effects on the course of diabetes.
play a role in the antidiabetic effect of leptin. In insulin-deficient diabetic animals, adiposity and plasma leptin levels decrease and food intake increases concomitantly (26). In our previous report, leptin administration reversed hyperphagia by correcting the imbalance in the hypothalamic neuropeptide expression in STZ-administered mice (7). Upregulation of orexigenic neuropeptides (neuropeptide Y and agouti-related peptide) and downregulation of anorexigenic neuropeptides (proopiomelanocortin) were observed in the hypothalamus of insulin-deficient diabetic mice (7,27). Leptin and insulin are crucial signals that convey “adiposity negative feedback” information to the hypothalamus. Our previous and present results indicate that leptin is useful for preventing diabetic hyperphagia.

Glucose-stimulated insulin secretion and pancreatic insulin content were markedly lower in both LepTg:Akita and Akita mice compared with WT and LepTg mice; however, both the plasma concentration and pancreatic content of glucagon decreased to the normal level in LepTg:Akita mice. Leptin is reported to suppress the synthesis and secretion of insulin by pancreatic β-cells (28,29). Our results did not reveal any negative effect of leptin on β-cell function in Akita mouse but showed that systemic hyperleptinemia plays a role in restoring the insulin-glucagon balance to proper equilibrium, which is lost in Akita mice. Wang et al. (30) reported recently that like insulin, leptin suppresses glucagon secretion in NOD mice. Our current data suggest that the antiglucagon and insulin-sensitizing effects of leptin on glucoregulatory hormones are therapeutically useful actions.

We found that chronic overexpression of leptin effectively prevented the development of diabetic nephropathy in Akita mice, as we have also demonstrated in lipoatrophic diabetic A-ZIP/F1 mice (31). Leptin suppressed the induction of massive albuminuria and the expansion of mesangial matrix accumulation are well-established features of diabetic nephropathy. Akita mice manifest the typical renal injury observed in human diabetic nephropathy that is associated

**FIG. 5. Urinary albumin excretion and histology of glomeruli. A: Time course of urinary albumin excretion of WT (◇), LepTg (◆), Akita (○), and LepTg:Akita (●). Data are expressed as means ± SE (n ≥ 4 in each group). §§P < 0.01 for WT vs. Akita, ¶¶P < 0.01 for LepTg vs. Akita, ★P < 0.01 for LepTg vs. LepTg:Akita, *P < 0.05, and **P < 0.01 for Akita vs. LepTg:Akita. B: PAS-staining of representative glomeruli from WT, LepTg, Akita, and LepTg:Akita mice at 22 weeks of age. Scale bar indicates 50 μm. (A high-quality color representation of this figure is available in the online issue.)**
injection of leptin, as shown in leptin-replacement therapy in LepTg mice is induced by transgenic overexpression. The therapeutic settings. Therapeutic leptinemia hyperglycemia in Akita mice (43). However, it is unclear associated viral vector expressing leptin also attenuates mice (42). Intracerebroventricular administration of adeno- b C/EBP- of the transcription factor C/EBP homologous protein gene metabolic processes of type 1 diabetes remains to be established. Leptin, a cytokine-like hormone, is suggested to be involved in linking nutritional status and immune response (45). Leptin administration accelerates autoimmune diabetes in NO mice, and the incidence of diabetes is significantly reduced in NOD mice and BB/Wor rats with Ob-R mutation (46–48). However, another study that assessed NOD mice with defective leptin signaling (Ag, db/db, and ob/ob) has shown that leptin is not essential for the development of autoimmune diabetes (49). Whether the beneficial effects of leptin in Akita mice can be translated to type 1 diabetes in humans will be important to determine.

Reduced insulin action in diabetes elevates plasma TG levels by decreasing lipoprotein lipase activity and increasing hormone-sensitive lipase activity. We demonstrated a significant reduction in plasma VLDL-TG level in LepTg mice (34). Leptin suppresses the activities of liver lipogenic enzymes (35,36). In LepTg:Akita mice, decreased levels of plasma lipids may also result from dwindling body fat stores (orthotopic and ectopic) because of augmented effects of leptin. Since hypertriglycerideremia is reported to be an independent cardiovascular risk factor in patients with glucose intolerance (37), our observation of the TG-lowering effects of leptin may be useful in preventing and treating diabetic cardiovascular complications.

Lipid peroxidation is a well-established mechanism of cellular injury as a diabetes complication and is used as an indicator of oxidative stress. Increased oxidative stress also participates in the development and progression of diabetes and its complications (38). LepTg:Akita mice maintained normal levels of plasma TBARS, in contrast to Akita mice. Increased levels of serum TBARS were reported in patients with peripheral arterial disease, ischemic heart disease, hypertension, and diabetes (39). Our finding that leptin relieved systemic oxidative stress in Akita mice is of interest because TBARS level does not depend only on the blood glucose or lipid level but reflects the complex redox balance (40,41).

Various interventions have been reported to improve the metabolic profiles in Akita mice (42,43). Targeted disruption of the transcription factor C/EBP homologous protein gene or C/EBP-β gene alleviates endoplasmic reticulum stress in pancreatic β-cells and improves hyperglycemia in Akita mice (42). Intracerebroventricular administration of adenoviral viral vector expressing leptin also attenuates hyperglycemia in Akita mice (43). However, it is unclear whether those interventions are directly applicable to the human therapeutic settings. Therapeutic leptinemia in LepTg mice is induced by transgenic overexpression. Leptinemia can be achieved clinically by subcutaneous injection of leptin, as shown in leptin-replacement therapy (11,12,44). Whether leptin affects the immunological processes of type 1 diabetes remains to be established. Leptin, a cytokine-like hormone, is suggested to be involved in linking nutritional status and immune response (45). Leptin administration accelerates autoimmune diabetes in NO mice, and the incidence of diabetes is significantly reduced in NOD mice and BB/Wor rats with Ob-R mutation (46–48). However, another study that assessed NOD mice with defective leptin signaling (Ag, db/db, and ob/ob) has shown that leptin is not essential for the development of autoimmune diabetes (49). Whether the beneficial effects of leptin in Akita mice can be translated to type 1 diabetes in humans will be important to determine.

In conclusion, the current study demonstrates that leptin has a therapeutic impact on the onset and progression of glucose intolerance, diabetes complications, and longevity in a mouse model of insulin-deficient nonobese diabetes. These data offer proof of concept that leptin may be useful as a long-term therapeutic agent for treating human diabetes.

**ACKNOWLEDGMENTS**

This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; the Ministry of Health, Labor, and Welfare of Japan; Takeda Medical Research Foundation; Smoking Research Foundation; Suzuken Memorial Foundation;...
Japan Foundation of Applied Enzymology; and Lilly Education and Research Grant Office and an award from Novo Nordisk Insulin Research. No other potential conflicts of interest relevant to this article were reported.

M.N. researched data. J.F. researched data and wrote the manuscript. K.E. contributed to discussion. F.M. researched data. H.Y. researched data and contributed to discussion. T.K., Y.Y., C.S., M.M., K.H., and K.N. contributed to discussion.

REFERENCES

1. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763–770
2. Ogawa Y, Masuzaki H, Hosoda K, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999;48:1822–1829
3. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995;1:1311–1314
4. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295
5. Eibihara K, Ogawa Y, Masuzaki H, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001;50:1440–1448
6. Kusakabe T, Tanioka H, Eibihara K, et al. Beneficial effects of leptin on glycemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 2006;49:675–682
7. Miyaoka F, Ogawa Y, Eibihara K, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetes 2003;43:1329–1337
8. Masuzaki H, Ogawa Y, Aizawa-Abe M, et al. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with leptin and yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 2009;58:1615–1622
9. Yoshida M, Kato T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese diabetic CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2009;30:377–393
10. Tanaka T, Hidaka S, Masuzaki H, et al. Skeletal muscle AMP-activated protein kinase activation during exercise: intact adipocytokine signaling is required. Front Immunol 2010;3:174–187
11. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008;105:14070–14075
12. Fukuwai T, Chuuang JC, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes in C57BL/6 J mice by CNS-dependent mechanisms in mice. Proc Natl Acad Sci USA 2010;107:17391–17396
13. Hosoda K, Masuzaki H, Ogawa Y, et al. Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 1996;221:234–239
14. MaffeI M, Halasa J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–1161
15. Enriori PJ, Evans AE, Sinnayah P, et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab 2007;5:181–194
16. Knight ZA, Hannon KS, Greenberg ML, Friedman JM. Hyperleptinemia is required for the development of leptin resistance. PLoS ONE 2010;5:e11376
17. Chinnokoswong N, Wang JL, Shi QZ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999;48:1487–1492
18. Sivitz WJ, Walsh S, Morgan D, Donohoue P, Haynes W, Leibel RL. Plasma leptin in diabetic and insulin-treated diabetic and normal rats. Metabolism 1998;47:584–591
19. Asakawa A, Toyoshima M, Inoue K, Koizumi A. Ins2Akita mice exhibit hyperphagia and anxiety behavior via the melanocortin system. Int J Mol Med 2007;19:649–652
20. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(Suppl. 1):S152–S158
21. Kulkarni RN, Wang ZL, Wang RM, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997;100:2729–2736
22. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type 1 diabetes. Proc Natl Acad Sci USA 2010;107:4813–4819
23. Suganami T, Mukoyama M, Mori K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 2005;19:127–129
24. Gurely SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 2009;290:F214–F222
25. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulonephrosis [see comments]. Kidney Int 1999;55:860–872
26. Matsumoto N, Ogawa Y, Masuzaki H, et al. Decreased triglyceride-rich lipoproteins in transgenic skinny mice overexpressing leptin. Am J Physiol Endocrinol Metab 2001;280:E334–E339
27. Gallardo N, Bonzioni-Kulinkenko E, Femández-Aguiló T, et al. Tissue-specific effects of central leptin on the expression of genes involved in lipid metabolism in liver and white adipose tissue. Endocrinology 2007;148:604–610
28. Cohen P, Miyaoka S, Socol ND, et al. Role for stearyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002;297:240–243
29. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–1861
30. Martim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24–38
31. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 1988;5:113–124
32. Altomare E, Vendemiale G, Cicchico D, Procacci V, Cirelli F. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Metabolism 1992;41:264–271
33. Fujimura Y, Kondo T, Murakami K, Kawakami Y. Decrease of the inhibition of lipid peroxidation by glutathione-dependent system in erythrocytes of non-insulin dependent diabetics. Klin Wochenschr 1989;67:336–341
34. Oyadomari S, Koizumi A, Takeda K, et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002;109:525–532
35. Ueno N, Inui A, Karla PS, Karla SP. Leptin transgene expression in the hypothalamus enhances euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese Ob/ob mice. Peptides 2006;27:2332–2342
36. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999;84:3686–3695
37. Matarasse G, Leiter EH, La Cava A. Leptin in autoimmunity: many questions, some answers. Tissue Antigens 2007;70:87–95
38. Matarasse G, Sanna C, Lechler RI, et al. Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes 2002;51:1356–1361
39. Lee CH, Reifsnyder PC, Nagisetty JK, et al. Novel leptin receptor mutation in NOD/Ltj mice: spontaneous correction of type 1 diabetes progression. J Pathophysiological analysis. Diabetes 2005;54:2325–2332
40. Guberski DI, Butler L, Manzi SM, Stubbs M, Lake AA. The BBZ/Wor rat: clinical characteristics of the diabetic syndrome. Diabetologia 1993;36:912–919
41. Nishimoto M, Miyamoto H. Immunopathological influence of the Ay, db, ob and nu genes placed on the inbred NOD background as murine models for human type 1 diabetes. J Immunogenet 1987;14:127–130